| Literature DB >> 31459413 |
André Rodrigues Sá Couto1, Alexey Ryzhakov1, Kim Lambertsen Larsen2, Thorsteinn Loftsson1.
Abstract
A detailed comprehensive study on how the formation of soluble and insoluble carbamazepine/cyclodextrins (CBZ/CD) complexes (with consequent changes in the solid-phase composition) depends on the CD structure is not yet available. Moreover, the study of possible influence of this drug on the tendency of CDs and their complexes to self-aggregate is still lacking. Phase-solubility studies demonstrated that CDs and CBZ form a range of soluble (AL-type: αCD, βCD, and hydroxypropylated CDs) and insoluble (BS-type: γCD) complexes depending on CD used. HPβCD proved to be the best CD solubilizer for CBZ forming the most stable complex with highest apparent solubility, whereas γCD was shown to be the best native CD. For the native CDs, CBZ solubilization increases with increasing CD cavity diameter (αCD ≪ βCD < γCD). Solid phases collected from phase-solubility studies were characterized by Fourier-transformed infrared spectroscopy, differential scanning calorimetry, and X-ray powder diffraction to elucidate their composition and crystalline structure. They provided similar conclusions being overall supportive of phase-solubility, osmolality, and permeation studies results. Solid CBZ was the only detected component for AL-type profiles over the CD concentration range studied, whereas precipitation of poorly soluble CBZ/γCD complexes (BS-type) was observed (i.e., at and beyond plateau region). Osmometry and permeation studies were applied to evaluate the effect of CBZ on the aggregate formation and also to elucidate their influence on CD complex solubility and permeation profile. Permeation method was shown to be the most effective method to detect and evaluate aggregate formation in aqueous γCD and HPβCD solutions containing CBZ. CBZ did not affect the HPβCD tendency to self-aggregate but CBZ did modify the aggregation behavior of γCD decreasing the apparent critical aggregation concentration value from 4.2% (w/v) (in pure aqueous γCD solution) to 2.5% (w/v) (when CBZ was present).Entities:
Year: 2019 PMID: 31459413 PMCID: PMC6648831 DOI: 10.1021/acsomega.8b02045
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1Phase-solubility profile describing solubility of CBZ in aqueous αCD, βCD, and γCD solutions at 25 °C. Symbols represent mean ± SD (n = 3).
Figure 2Obtained phase-solubility profiles for HP-CDs with CBZ (25 °C). Symbols represent mean ± SD (n = 3).
Type of Profile, Apparent Stability Constant (K1:1), CE and Maximum Increase (in Percentage) in Apparent Solubility of CBZ per mM of CD (IS) in the Different Aqueous CBZ/CD Complex Solutions at 25 °Ca
| carbamazepine (CBZ) | |||||
|---|---|---|---|---|---|
| CD | type | slope | CE | IS (%) | |
| αCD | AL | 0.006 | 8.9 | 0.006 | 0.97 |
| βCD | AL | 0.348 | 840.5 | 0.53 | 56.4 |
| γCD | BS | 0.441 | 1245.1 | 0.79 | 69.9 |
| HPαCD | AL | 0.022 | 31.4 | 0.02 | 3.4 |
| HPβCD | AL | 0.699 | 3299.5 | 2.33 | 110.1 |
| HPγCD | AL | 0.189 | 369.0 | 0.23 | 31.5 |
Phase-solubility diagrams built with actual CD concentrations instead of theoretical CD concentrations only showed some differences for the B-type diagrams (i.e., beyond the plateau region). As their initial linear part (i.e., before the plateau region) showed negligible changes, Higuchi–Connors classification could still be used.
AL: linear phase-solubility diagram and BS: phase-solubility diagram with linear initial increase, a plateau and a decreasing terminal solubility.[30]
Variation of Solid-Phase Composition with Phase-Solubility Type Profile and CD Concentration
| phase-solubility profile | solid phase’s composition |
|---|---|
| A-type | highly soluble complexes remaining in solution. |
| only excess of pure drug can be detected in solid phase. | |
| B-type | content of solid phase will vary with CD concentration and surplus amount of model drug. |
Figure 3(a) Changes of total osmolality for the prepared CBZ/αCD and CBZ/γCD systems during phase-solubility experiments (25 °C). (b) Changes of total osmolality for the CBZ/βCD systems during phase-solubility experiments (25 °C). Symbols represent mean ± SD (n = 3).
Figure 4Total osmolality changes for of the prepared CBZ/HP-CD systems during phase-solubility experiments (25 °C). Symbols represent mean ± SD (n = 3).
Figure 5Illustration of α- and γCD (a) and βCD (b) solubility in the prepared CBZ/CD systems. Symbols represent mean ± SD (n = 3).
Figure 6Illustration of HP-CDs solubility in the prepared CBZ/HP-CD systems. Symbols represent mean ± SD (n = 3).
Figure 7Flux profile of HPβCD from HPβCD aqueous solution (filled squares) and CBZ/HPβCD liquid phases (empty circles) through 3.5–5 kDa MWCO semipermeable membrane.
Figure 8Flux profile of γCD in aqueous γCD solution (filled squares) and γCD from CBZ/γCD liquid phases (empty circles) through 3.5–5 kDa MWCO semipermeable membrane.
Figure 9Flux profile of CBZ from CBZ/HPβCD liquid phases (a) and of CBZ from CBZ/γCD liquid phases (b) through 3.5–5 kDa MWCO semipermeable membrane.
Figure 10Schematic representation of native and hydroxypropylated CDs (A) and CBZ (B). Adapted from ref (39).